Tom Brady & Linda Yaccarino on Startup eMed, GLP-1s

Summary

Tom Brady and Linda Yaccarino discuss their involvement with eMed, a telehealth startup focused on GLP-1 weight-loss medications. They highlight the company's partnership with CVS and Aon, the expansion of the market via oral pills, and the importance of proactive health management. No specific investment recommendations are made.

• Linda Yaccarino explains her move from X (Twitter) to eMed, citing the transformative power of GLP-1 medications.
• Tom Brady discusses his investment in eMed, emphasizing proactive health and meeting people where they are.
• eMed requires patients to qualify via blood tests, differentiating it from other telehealth companies.
• The cost of GLP-1 drugs is decreasing, making employer coverage more feasible.
• Oral GLP-1 pills are seeing unprecedented adoption, especially among men.
• eMed has strategic partnerships with CVS and Aon.
• Tom Brady plans to stay involved in football, including potential Raiders ownership.
• The conversation focuses on business strategy, not public market investments.